Number of items: 2.
Mohr, P; Hauschild, A; Trefzer, U; Enk, A; Tilgen, W; Loquai, C; Gogas, H; Haalck, T; Koller, J; Dummer, R; Gutzmer, R; Brockmeyer, N; Holzle, E; Sunderkotter, C; Mauch, C; Stein, A; Schneider, L A; Podda, M; Goppner, D; Schadendorf, D; Weichenthal, M (2015). Intermittent high-dose intravenous interferon Alfa-2b for adjuvant treatment of stage III melanoma: Final analysis of a randomized phase III dermatologic cooperative oncology group trial. Journal of Clinical Oncology, 33(34):4077-4084.
Hassel, J C; Sucker, A; Edler, L; Kurzen, H; Moll, I; Stresemann, C; Spieth, K; Mauch, C; Rass, K; Dummer, R; Schadendorf, D (2010). MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. British Journal of Cancer, 103(6):820-826.
This list was generated on Wed Jul 26 10:04:26 2017 CEST.
